Jump to main content
Jump to site search

Issue 46, 2017
Previous Article Next Article

A metabolomics approach to profiling the cardioprotective effect of LCZ696, an angiotensin receptor-neprilysin inhibitor, on ischemia induced heart failure

Author affiliations

Abstract

Heart failure is one of the most common chronic diseases in the world, particularly among the elderly, yet, no clinically approved metabolite biomarkers have been identified so far. To address this issue, we conducted a liquid-chromatography study with time-of-flight mass spectrometer (LC/Q-TOF-MS)-based metabolomics to investigate heart failure and to assess the efficacies and mechanisms of LCZ696, which is a novel angiotensin receptor neprilysin inhibitor in treating heart failure in mice induced by coronary artery ligation. Based on unsupervised principal component analysis, a clear separation was observed between the heart failure and sham-operated group, which revealed that heart failure disturbed the metabolism of endogenous substances and significantly altered the heart metabolite fingerprints. After LCZ696 treatment, the metabolomics profile found in heart failure was significantly reversed, shifting much closer to sham controls, confirming that LCZ696 had therapeutic effects in heart failure. Metabolomic pathway analysis revealed that several pathways including fatty acid metabolism, lipid metabolism, glucose metabolism, and amino acid metabolism were significantly altered in heart failure mice. Consequently, it was inferred that LCZ696 shows therapeutic efficacy in heart failure by restoring these disturbed metabolic pathways, especially the ones related to energy metabolism. To conclude, the present study provides a new methodological approach for understanding heart failure and LCZ696 mechanisms relevant for heart failure treatment.

Graphical abstract: A metabolomics approach to profiling the cardioprotective effect of LCZ696, an angiotensin receptor-neprilysin inhibitor, on ischemia induced heart failure

Back to tab navigation

Supplementary files

Article information


Submitted
03 Feb 2017
Accepted
15 May 2017
First published
05 Jun 2017

This article is Open Access

RSC Adv., 2017,7, 29170-29183
Article type
Paper

A metabolomics approach to profiling the cardioprotective effect of LCZ696, an angiotensin receptor-neprilysin inhibitor, on ischemia induced heart failure

Y. Xia, Z. Chen, A. Chen, D. Lu, J. Jia, Y. Zou, J. Qian and J. Ge, RSC Adv., 2017, 7, 29170
DOI: 10.1039/C7RA01404J

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

Reproduced material should be attributed as follows:

  • For reproduction of material from NJC:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
  • For reproduction of material from PCCP:
    [Original citation] - Published by the PCCP Owner Societies.
  • For reproduction of material from PPS:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
  • For reproduction of material from all other RSC journals:
    [Original citation] - Published by The Royal Society of Chemistry.

Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.


Social activity

Search articles by author

Spotlight

Advertisements